Evrenzo (roxadustat)
- Region
- 🇪🇺 EU
- Active substance
- roxadustat
- Company
- Astellas Pharma Europe B.V.
- Status
- Authorised
- Therapeutic area
- Anemia; Kidney Failure, Chronic
- CHMP opinion
- Thu 24 Jun 2021
- EU approval
- Wed 18 Aug 2021
- Application
- EMEA/H/C/004871
- ATC
- B03XA05
- Official record
- www.ema.europa.eu
Indication
Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).
Regulatory milestones
No milestones recorded in the last year.
Follow Evrenzo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.